AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors

 
• By Joseph Haas

Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.

Sales decline
Humira suffered significant biosimilar erosion during Q1, but it was in line with projections • Source: Shutterstock

More from Earnings

More from Business